Browsing Tag
Vanda Pharmaceuticals Inc.
3 posts
Vanda Pharmaceuticals VQW-765 fails Phase 3 anxiety trial as stock faces fresh pressure
Vanda Pharmaceuticals has paused development of VQW-765 after a 546-patient Phase 3 study failed to demonstrate a significant reduction in social anxiety symptoms. The setback removes a near-term clinical catalyst, placing greater importance on its commercial product launches, cash position and remaining regulatory milestones.
Vanda Pharmaceuticals (VNDA) bets on GLP-1 adherence gap with new Nereus vomiting-prevention study
Vanda Pharmaceuticals has launched the Thetis study to test Nereus in GLP-1-related vomiting. Read what this means for obesity drug adherence and VNDA.
Vanda Pharmaceuticals (NASDAQ: VNDA) gains after FDA sets new December 5 date for tradipitant re-review
Vanda Pharmaceuticals moves closer to FDA approval for tradipitant in motion sickness while targeting the GLP-1 side effect market. Find out what’s next.